Literature DB >> 10468612

The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

C Gobert1, A Skladanowski, A K Larsen.   

Abstract

DNA topoisomerase I is a nuclear enzyme involved in transcription, recombination, and DNA damage recognition. Previous studies have shown that topoisomerase I interacts directly with the tumor-suppressor protein p53. p53 is a transcription factor that activates certain genes through binding to specific DNA sequences. We now report that topoisomerase I can be stimulated by both latent and activated wild-type p53 as well as by several mutant and truncated p53 proteins in vitro, indicating that sequence-specific DNA-binding and stimulation of topoisomerase I are distinct properties of p53. These assays also suggest that the binding site for topoisomerase I on p53 is between amino acids 302 and 321. In living cells, the interaction between p53 and topoisomerase I is strongly dependent on p53 status. In MCF-7 cells, which have wild-type p53, the association between the two proteins is tightly regulated in a spatial and temporal manner and takes place only during brief periods of genotoxic stress. In marked contrast, the two proteins are constitutively associated in HT-29 cells, which have mutant p53. These findings have important implications for both cellular stress response and genomic stability, given the ability of topoisomerase I to recognize DNA lesions as well as to cause illegitimate recombination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468612      PMCID: PMC17892          DOI: 10.1073/pnas.96.18.10355

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.

Authors:  M M Heck; W N Hittelman; W C Earnshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination.

Authors:  P Bullock; J J Champoux; M Botchan
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

3.  Subnuclear particles containing a small nuclear RNA and heterogeneous nuclear RNA.

Authors:  G Zieve; S Penman
Journal:  J Mol Biol       Date:  1981-01-25       Impact factor: 5.469

4.  Association of eukaryotic DNA topoisomerase I with nucleosomes and chromosomal proteins.

Authors:  K Javaherian; L F Liu
Journal:  Nucleic Acids Res       Date:  1983-01-25       Impact factor: 16.971

5.  Mammalian topoisomerase I has base mismatch nicking activity.

Authors:  Y C Yeh; H F Liu; C A Ellis; A L Lu
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

6.  Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome.

Authors:  G Fleischmann; G Pflugfelder; E K Steiner; K Javaherian; G C Howard; J C Wang; S C Elgin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  Allosteric activation of latent p53 tetramers.

Authors:  T R Hupp; D P Lane
Journal:  Curr Biol       Date:  1994-10-01       Impact factor: 10.834

Review 8.  International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.

Authors:  R D Anderson; N A Berger
Journal:  Mutat Res       Date:  1994-08-01       Impact factor: 2.433

9.  Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.

Authors:  S D Baker; R M Wadkins; C F Stewart; W T Beck; M K Danks
Journal:  Cytometry       Date:  1995-02-01

10.  p53 oligomerization and DNA looping are linked with transcriptional activation.

Authors:  J E Stenger; P Tegtmeyer; G A Mayr; M Reed; Y Wang; P Wang; P V Hough; I A Mastrangelo
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

View more
  26 in total

Review 1.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro.

Authors:  Holger Stephan; Frank Grosse; Kent Søe
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

4.  p53 stimulates human topoisomerase I activity by modulating its DNA binding.

Authors:  Kent Søe; Frank Grosse
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

5.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 6.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 7.  Controlling gene expression by DNA mechanics: emerging insights and challenges.

Authors:  David Levens; Laura Baranello; Fedor Kouzine
Journal:  Biophys Rev       Date:  2016-11-14

Review 8.  Controlling gene expression by DNA mechanics: emerging insights and challenges.

Authors:  David Levens; Laura Baranello; Fedor Kouzine
Journal:  Biophys Rev       Date:  2016-08-20

9.  Transcriptional consequences of topoisomerase inhibition.

Authors:  I Collins; A Weber; D Levens
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 10.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.